Production (Stage)
Innate Pharma S.A.
IPHA
$2.08
-$0.09-4.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.65M | 20.26M | 26.89M | 41.66M | 56.11M |
| Total Other Revenue | 8.11M | 8.91M | 9.67M | 10.13M | 10.53M |
| Total Revenue | 21.76M | 29.16M | 36.56M | 51.79M | 66.64M |
| Cost of Revenue | 56.23M | 57.25M | 58.03M | 59.50M | 60.58M |
| Gross Profit | -34.46M | -28.08M | -21.47M | -7.71M | 6.06M |
| SG&A Expenses | 21.33M | 20.85M | 20.26M | 20.08M | 19.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 77.56M | 78.10M | 78.28M | 79.57M | 80.36M |
| Operating Income | -55.79M | -48.93M | -41.73M | -27.78M | -13.71M |
| Income Before Tax | -53.52M | -45.35M | -36.82M | -22.56M | -8.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.52 | -45.35 | -36.82 | -22.56 | -8.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.52M | -45.35M | -36.82M | -22.56M | -8.20M |
| EBIT | -55.79M | -48.93M | -41.73M | -27.78M | -13.71M |
| EBITDA | -54.39M | -47.32M | -39.92M | -24.62M | -9.24M |
| EPS Basic | -0.66 | -0.56 | -0.46 | -0.28 | -0.10 |
| Normalized Basic EPS | -0.41 | -0.35 | -0.28 | -0.17 | -0.06 |
| EPS Diluted | -0.66 | -0.56 | -0.46 | -0.28 | -0.10 |
| Normalized Diluted EPS | -0.41 | -0.35 | -0.28 | -0.18 | -0.06 |
| Average Basic Shares Outstanding | 324.21M | 323.56M | 322.92M | 322.37M | 321.81M |
| Average Diluted Shares Outstanding | 324.21M | 323.56M | 322.92M | 327.95M | 330.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |